<DOC>
	<DOCNO>NCT02028676</DOCNO>
	<brief_summary>The two original objective determine HIV-infected child initiate antiretroviral therapy ( ART ) : 1 . Whether clinically drive monitoring ( CDM ) similar outcome term disease progression death routine laboratory clinical monitoring ( LCM ) toxicity ( haematology/biochemistry ) efficacy ( CD4 ) ? 2 . Whether induction four drug two ART class follow maintenance three drug 36 week effective continuous non-nucleoside reverse transcriptase inhibitor ( NNRTI ) -based triple drug regimen term CD4 clinical outcome ? Two secondary objective determine 3 . Whether change twice daily lamivudine+abacavir daily lamivudine+abacavir 48 week ART similar outcome term virological suppression result improvement adherence ART ? 4 . Whether stop daily cotrimoxazole prophylaxis child 3 year age ART least 96 week similar outcome term hospitalisation death continue daily cotrimoxazole ?</brief_summary>
	<brief_title>Efficacy Study Different Laboratory Management Strategies Drug Regimens HIV-infected Children Africa</brief_title>
	<detailed_description>The ARROW ( AntiRetroviral Research fOr Watoto ) protocol describe open-label randomised trial primarily evaluate two strategic approach management antiretroviral therapy ( ART ) 1200 symptomatic HIV-infected infant child initiate ART follow WHO guideline Uganda Zimbabwe . The first strategy compare clinically drive monitoring ( CDM ) laboratory plus clinical monitoring ( LCM ) . In group , test toxicity ( standard haematology biochemistry panel ) efficacy ( lymphocyte subset include CD4 count ) do every 12 week . In LCM , result return patient management . In CDM , physician may request result routine haematology/biochemistry panel need clinical management , result return routinely , lymphocyte subset never return . Extra laboratory test may request outside scheduled visit time either group ( except lymphocyte subset CDM ) . The second strategy compare continuous WHO-recommended first-line ART three-drug two-class regimen , comprise two Nucleoside Reverse Transcriptase Inhibitors ( NRTIs ) plus one Non-Nucleoside Reverse Transcriptase Inhibitor ( NNRTI ) , induction four drug ( two class ) 36 week follow maintenance three drug . After least 36 96 week ART respectively , two randomisation assess simplification strategy could improve long-term ART adherence ( ) versus twice daily lamivudine+abacavir NRTI drug ( ii ) stop versus continue daily cotrimoxazole prophylaxis .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<criteria>For initial randomisation CDM v LCM , ART induction strategy : 1 . Children adult carer household either : participate DART trial OR treat ART OR HIV positive yet need treatment access treatment programme ART require OR HIV negative . Children DART participant first priority available remain slot enter ARROW . 2 . Parents guardian , child appropriate accord age knowledge HIV status , must willing able give inform consent randomisation CDM LCM firstline ART strategy . 3 . Participants must confirm documented diagnosis HIV1 infection : 1 . For child age 18 month : two separate peripheral blood specimen different day , result positive HIVDNA polymerase chain reaction ( PCR ) . 2 . For child age 18 month : antibody positive serology ELISA test ( confirm license second ELISA Western Blot ) WHO approve rapid test ( performed series ) sample . Any child previously test another clinic repeat test ARROW screen laboratory confirm status . 4 . Age 3 month 17 year ( 1317 year cap 10 % ) 5 . ART na√Øve ( except exposure perinatal ART prevention mothertochild HIV transmission ) . 6 . Meeting criterion require ART accord WHO stage CD4 percent count : WHO paediatric clinical stage IV disease : treat regardless CD4 percent count WHO paediatric clinical stage III disease : &lt; 12 month : treat &gt; 12 month : treat child irrespective CD4 percent count ; however , child age &gt; 12 month tuberculosis , lymphocytic interstitial pneumonia ( LIP ) , oral hairy leukoplakia ( OHP ) thrombocytopenia ( low platelet count treat ) guide CD4 cell assay ( see ) . WHO paediatric clinical stage II I disease : treat guide CD4 percent count CD4 % &lt; 25 % infant &lt; 12 month ; CD4 % &lt; 20 % child 1 &lt; 3 year ; CD4 % &lt; 15 % child 3 &lt; 5years ; CD4 % &lt; 15 % child &gt; 5years ( consideration also take CD4 count . A CD4 count &lt; 200 cells/mm3 use guide start ART CD4 generally &lt; 350 cells/mm3 . ) 1 . Can , unlikely attend regularly ( e.g . usual residence far study centre ) 2 . Likelihood poor adherence 3 . Presence acute infection ( e.g . malaria , helminthiasis , acute hepatitis , acute pneumonia , septicaemia , meningitis ) . Children may admit recovery acute infection . Children chronic lung disease , include recurrent respiratory infection , eligible . Children tuberculosis ( TB ) enrol intensive phase antituberculosis therapy , reevaluate intensive phase decision make start ART ( see 4 ) 4 . In receipt medication contraindicate ART child three year age receive antituberculosis therapy enrol ( receive nevirapine ) . chemotherapy malignancy 5 . Laboratory abnormality contraindication child start ART ( haemoglobin &lt; 8.5g/dL ; neutrophil &lt; 0.50x109/L ; aspartate transaminase ( AST ) alanine transaminase ( ALT ) &gt; 5 x upper limit normal ( ULN ) ; grade 3 renal dysfunction creatinine &gt; 1.9 x ULN ) . N.B . cause anaemia , concurrent bacterial infection , malaria , helminthiasis and/or malnutrition investigate , treatment anaemia cause commenced prior rescreening eligibility . 6 . Being pregnant breastfeeding infant 7 . Perinatal exposure nevirapine ( either prevention mothertochild transmission ( pMTCT ) breastfeeding ) child age 3 6 month Eligibility criteria secondary randomisation v twice daily lamivudine+abacavir Inclusion criterion 1 . Participating ARROW 2 . On ART least 36 week 3 . Currently take lamivudine+abacavir twice daily part ART regimen expect stay two drug least next 12 week 4 . Parents guardian , child appropriate accord age knowledge HIV status , must willing able give inform consent randomisation twice daily lamivudine+abacavir Exclusion criterion 5 . Likely switch secondline therapy next 12 week Eligibility criterion secondary randomisation stop continue cotrimoxazole prophylaxis randomisation Inclusion criterion 1 . Participating ARROW 2 . Aged least 3 year 3 . Initiated ART least 96 week previously , receive least 96 week ART allow interruption ART 4 . Currently prescribe daily cotrimoxazole primary prophylaxis 5 . Parents guardian , child appropriate accord age knowledge HIV status , must willing able give inform consent randomisation stop continue daily cotrimoxazole prophylaxis 6 . If living malaria endemic area , insecticide treat bednet prepare use child . Exclusion criteria 7 . Previous diagnosis Pneumocystis jiroveci pneumonia ( cotrimoxazole secondary prophylaxis discontinue )</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>HIV</keyword>
	<keyword>Africa</keyword>
	<keyword>child</keyword>
	<keyword>antiretroviral therapy</keyword>
	<keyword>laboratory monitoring</keyword>
	<keyword>toxicity</keyword>
	<keyword>CD4</keyword>
	<keyword>induction maintenance</keyword>
	<keyword>cotrimoxazole</keyword>
	<keyword>prophylaxis</keyword>
	<keyword>abacavir</keyword>
	<keyword>lamivudine</keyword>
	<keyword>daily</keyword>
</DOC>